Acute heart failure after treatment with 5-fluorouracil

Journal of B.U.ON.

Volumn 12, Issue 1, 2007, Pages 113-116

  Georgieva, S ^a   Kinova, E ^a   Iordanov, Victor ^b   Gudev, A ^a   Tzekova, V ^a   Velikova, M ^a  

^a Queen Giovanna Hospital   (Bulgaria)

^b National Oncology Center Bulgaria   (Bulgaria)

Author keywords

5 fluorouracil; Cardiotoxicity; Chest pain

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; MORPHINE; NITRATE; ONDANSETRON; OXALIPLATIN; TRIMETAZIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE HEART FAILURE; ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; CHOLECYSTECTOMY; CLINICAL EXAMINATION; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DRUG INDUCED HEADACHE; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; HEART AUSCULTATION; HEART VENTRICLE FILLING; HEART VENTRICLE REMODELING; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HYPOXIA; LIVER METASTASIS; LUNG AUSCULTATION; LUNG EDEMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NAUSEA; POSTOPERATIVE PERIOD; REOPERATION; SINUS TACHYCARDIA; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ACUTE DISEASE; ANGINA PECTORIS; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DRUG ADMINISTRATION; ELECTROCARDIOGRAPHY; FORWARD HEART FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY;

ACUTE DISEASE; ANGINA PECTORIS; ANTIMETABOLITES, ANTINEOPLASTIC; CARDIAC OUTPUT, LOW; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PULMONARY EDEMA;

EID: 34249734696     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71: 493-499.
2. Wittes R (Ed). Mannual of Oncology Therapeutics. JB Lippincott, Philadelphia 1991/92, pp 99-101.
3. De Fomi M, Malet-Martino MC, Jaillais P et al. Cardiotoxicity of high dose continuous infusion of fluorouracil: prospective clinical study. J Clin Oncol 1992; 10: 1795-1801.
4. Spasojevica I, Zakrzewskac J, Bacica G. 31 PN MR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity related changes in ATP, 2, 3-BPG and O2 metabolism. Ann New York Acad Sci 2005, 1048, p 311.
5. Kuropkat Chr, Griem K, Clark J et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22: 466.
6. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33: 1060-1070.
7. Becker K, Erckenbrecht JE, Haussinger D et al. Cardiotoxicity of the antiproliferative compound of 5-fluorouracil. Drugs 1999; 57: 475-484.
8. Weidmann B, Teipel A, Niederle N. The syndrome of 5-fluorouracil cardiotoxicity: An elusive cardiopathy. Cancer 1994; 73: 2001-2002.
9. Shoemaker LK, Umesh A, Caio MS, Rocha Limsa S. 5-FU induces coronary vasospasm. Cancer Control 2004; 11: 46-49.
10. Sudhoff T, Endrele M, Pahlke Metal. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15: 661-664.
11. Fornim D, Bugat R, Sorbette F et al. Cardiotoxicity of continuous intravenous infusion of 5-FU: clinical study, prevention and physiopathology. Apropos of 13 cases. Bull Cancer 1990; 77: 429-438.
12. Van Custe E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002 13: 484-485.
13. Meydan N, Kundak I, Yavuzsen T et al. Cardiotoxicity of the Gramont's regime: incidence, clinical characteristics and long term follow-up. Jpn J Clin Oncol 2005; 35: 265-270.
14. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombic treatment in protection against thrombogenic effects of 5-FU on vascular endothelium. Scanning 2001; 23:1-8.